• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

RNA N1-甲基腺苷调节因子介导的甲基化修饰模式和胶质瘤的异质性特征。

RNA N1-methyladenosine regulator-mediated methylation modification patterns and heterogeneous signatures in glioma.

机构信息

Department of Anesthesiology and Perioperative Medicine, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.

Research of Trauma Center, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.

出版信息

Front Immunol. 2022 Jul 22;13:948630. doi: 10.3389/fimmu.2022.948630. eCollection 2022.

DOI:10.3389/fimmu.2022.948630
PMID:35936006
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9354098/
Abstract

N1-methyladenosine (mA) is ubiquitous in eukaryotic RNA and regulates mRNA translation. However, little is known about its regulatory role in glioma. Here, we identified 4 mA modification-related patterns based on mA regulators in the TCGA (The Cancer Genome Atlas) and CGGA (Chinese Glioma Genome Atlas) cohorts. The differences in survival prognosis between different clusters were striking. In addition, stemness, genomic heterogeneity, tumor microenvironment (TME), and immune cell infiltration were also significantly different between the poor and best prognostic clusters. To reveal the underlying mechanism, differentially expressed genes (DEGs) between the poor and best prognostic clusters were identified, and then were integrated for weighted correlation network analysis (WGCNA). After Univariate Cox-LASSO-Multivariate Cox analyses, DEGs PLEK2 and ABCC3 were screened as the risk-hub genes and were selected to construct an mA-related signature. Moreover, ABCC3 exacerbated glioma proliferation and was associated with temozolomide (TMZ) resistance. Overall, our study provided new insights into the function and potential therapeutic role of mA in glioma.

摘要

N1-甲基腺苷（mA）在真核 RNA 中普遍存在，可调节 mRNA 翻译。然而，mA 在神经胶质瘤中的调控作用知之甚少。在此，我们基于 TCGA（癌症基因组图谱）和 CGGA（中国脑胶质瘤基因组图谱）队列中的 mA 调节因子，鉴定了 4 种 mA 修饰相关模式。不同聚类之间的生存预后差异显著。此外，在预后不良和最佳预后聚类之间，干性、基因组异质性、肿瘤微环境（TME）和免疫细胞浸润也存在显著差异。为了揭示潜在的机制，我们鉴定了预后不良和最佳预后聚类之间的差异表达基因（DEGs），然后进行加权相关网络分析（WGCNA）的整合。经过单变量 Cox-LASSO-多变量 Cox 分析，筛选出差异表达基因 PLEK2 和 ABCC3 作为风险枢纽基因，并选择构建 mA 相关特征。此外，ABCC3 可加重神经胶质瘤的增殖，并与替莫唑胺（TMZ）耐药相关。总之，我们的研究为 mA 在神经胶质瘤中的功能和潜在治疗作用提供了新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/238d51609c28/fimmu-13-948630-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/26f019a99a6f/fimmu-13-948630-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/23e4dbf9c74b/fimmu-13-948630-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/358fcd028781/fimmu-13-948630-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/5669078b3e4b/fimmu-13-948630-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/1dbada5e2198/fimmu-13-948630-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/4c33041dfad4/fimmu-13-948630-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/0b00271e0c7e/fimmu-13-948630-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/3bf6656ca9ae/fimmu-13-948630-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/4201f0f02184/fimmu-13-948630-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/530e57df499b/fimmu-13-948630-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/238d51609c28/fimmu-13-948630-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/26f019a99a6f/fimmu-13-948630-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/23e4dbf9c74b/fimmu-13-948630-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/358fcd028781/fimmu-13-948630-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/5669078b3e4b/fimmu-13-948630-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/1dbada5e2198/fimmu-13-948630-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/4c33041dfad4/fimmu-13-948630-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/0b00271e0c7e/fimmu-13-948630-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/3bf6656ca9ae/fimmu-13-948630-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/4201f0f02184/fimmu-13-948630-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/530e57df499b/fimmu-13-948630-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f3cf/9354098/238d51609c28/fimmu-13-948630-g011.jpg

相似文献

1
RNA N1-methyladenosine regulator-mediated methylation modification patterns and heterogeneous signatures in glioma.RNA N1-甲基腺苷调节因子介导的甲基化修饰模式和胶质瘤的异质性特征。
Front Immunol. 2022 Jul 22;13:948630. doi: 10.3389/fimmu.2022.948630. eCollection 2022.
2
Comprehensive analysis of mA/mC/mA-related gene expression, immune infiltration, and sensitivity of antineoplastic drugs in glioma.全面分析脑胶质瘤中 mA/mC/mA 相关基因表达、免疫浸润和抗肿瘤药物敏感性。
Front Immunol. 2022 Sep 20;13:955848. doi: 10.3389/fimmu.2022.955848. eCollection 2022.
3
Identification of M5c regulator-medicated methylation modification patterns for prognosis and immune microenvironment in glioma.鉴定 M5c 调节剂介导的甲基化修饰模式，用于预测胶质瘤的预后和免疫微环境。
Aging (Albany NY). 2023 Nov 6;15(21):12275-12295. doi: 10.18632/aging.205179.
4
The hub ten gene-based risk score system using RNA mA methylation regulator features and tumor immune microenvironment in breast cancer.基于 hub 十基因的风险评分系统，利用 RNA mA 甲基化调节剂特征和乳腺癌肿瘤免疫微环境。
Breast Cancer. 2022 Jul;29(4):645-658. doi: 10.1007/s12282-022-01341-5. Epub 2022 Feb 16.
5
Identification of Critical mA RNA Methylation Regulators with Prognostic Value in Lower-Grade Glioma.低级别胶质瘤中具有预后价值的关键 mA RNA甲基化调控因子的鉴定
Biomed Res Int. 2021 Jun 8;2021:9959212. doi: 10.1155/2021/9959212. eCollection 2021.
6
Using integrated analysis from multicentre studies to identify RNA methylation-related lncRNA risk stratification systems for glioma.利用多中心研究的综合分析来确定胶质瘤的RNA甲基化相关长链非编码RNA风险分层系统。
Cancer Cell Int. 2023 Aug 5;23(1):156. doi: 10.1186/s12935-023-03001-w.
7
Establishment of a N1-methyladenosine-related risk signature for breast carcinoma by bioinformatics analysis and experimental validation.基于生物信息学分析和实验验证建立乳腺癌 N1-甲基腺苷相关风险特征。
Breast Cancer. 2023 Jul;30(4):666-684. doi: 10.1007/s12282-023-01458-1. Epub 2023 May 13.
8
Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.鉴定一个与肿瘤微环境相关的七基因标志物，用于预测膀胱癌的预后。
BMC Cancer. 2021 Jun 10;21(1):692. doi: 10.1186/s12885-021-08447-7.
9
Prognostic Value of a Stemness Index-Associated Signature in Primary Lower-Grade Glioma.干性指数相关特征在原发性低级别胶质瘤中的预后价值
Front Genet. 2020 May 5;11:441. doi: 10.3389/fgene.2020.00441. eCollection 2020.
10
N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.N6-甲基腺苷RNA甲基化调节因子相关的可变剪接基因特征作为低级别胶质瘤患者的预后预测指标及免疫微环境特征分析
Front Genet. 2022 Jul 22;13:872186. doi: 10.3389/fgene.2022.872186. eCollection 2022.

引用本文的文献

1
The role of RNA methylation in glioma progression: mechanisms, diagnostic implications, and therapeutic value.RNA甲基化在神经胶质瘤进展中的作用：机制、诊断意义及治疗价值
Front Immunol. 2025 May 21;16:1583039. doi: 10.3389/fimmu.2025.1583039. eCollection 2025.
2
Genetic variants of mA modification genes and the risk of neuroblastoma: novel insights from a Chinese case-control study.mA修饰基因的遗传变异与神经母细胞瘤风险：一项中国病例对照研究的新见解
Hum Genomics. 2025 May 8;19(1):50. doi: 10.1186/s40246-025-00767-0.
3
Analysis of ABCC3 in glioma progression: implications for prognosis, immunotherapy, and drug resistance.

本文引用的文献

1
The epitranscriptome toolbox.表观转录组工具箱。
Cell. 2022 Mar 3;185(5):764-776. doi: 10.1016/j.cell.2022.02.007.
2
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity.发育和损伤反应转录状态梯度定义了支持胶质母细胞瘤异质性的功能脆弱性。
Nat Cancer. 2021 Feb;2(2):157-173. doi: 10.1038/s43018-020-00154-9. Epub 2021 Jan 4.
3
Gene Expression-Based Predication of RNA Pseudouridine Modification in Tumor Microenvironment and Prognosis of Glioma Patients.
ABCC3在胶质瘤进展中的分析：对预后、免疫治疗和耐药性的影响
Discov Oncol. 2025 Feb 13;16(1):179. doi: 10.1007/s12672-025-01895-8.
4
Integrating bulk and single-cell RNA sequencing data: unveiling RNA methylation and autophagy-related signatures in chronic obstructive pulmonary disease patients.整合批量和单细胞RNA测序数据：揭示慢性阻塞性肺疾病患者的RNA甲基化和自噬相关特征
Sci Rep. 2025 Feb 1;15(1):4005. doi: 10.1038/s41598-025-87437-2.
5
RNA modifications in cancer.癌症中的RNA修饰
MedComm (2020). 2025 Jan 10;6(1):e70042. doi: 10.1002/mco2.70042. eCollection 2025 Jan.
6
Clinician's Guide to Epitranscriptomics: An Example of N-Methyladenosine (mA) RNA Modification and Cancer.表观转录组学临床医生指南：以N-甲基腺苷（m⁶A）RNA修饰与癌症为例
Life (Basel). 2024 Sep 25;14(10):1230. doi: 10.3390/life14101230.
7
Two decades of progress in glioma methylation research: the rise of temozolomide resistance and immunotherapy insights.胶质瘤甲基化研究二十年进展：替莫唑胺耐药性的出现及免疫治疗见解
Front Neurosci. 2024 Sep 2;18:1440756. doi: 10.3389/fnins.2024.1440756. eCollection 2024.
8
Transcriptome-wide 1-methyladenosine functional profiling of messenger RNA and long non-coding RNA in bladder cancer.膀胱癌中信使核糖核酸和长链非编码核糖核酸的全转录组范围1-甲基腺苷功能分析
Front Genet. 2024 Feb 28;15:1333931. doi: 10.3389/fgene.2024.1333931. eCollection 2024.
9
Research progress of N1-methyladenosine RNA modification in cancer.N1-甲基腺苷 RNA 修饰在癌症中的研究进展。
Cell Commun Signal. 2024 Jan 30;22(1):79. doi: 10.1186/s12964-023-01401-z.
10
Molecular and clinical characterization of ANG expression in gliomas and its association with tumor-related immune response.胶质瘤中ANG表达的分子与临床特征及其与肿瘤相关免疫反应的关联
Front Med (Lausanne). 2023 Oct 19;10:1044402. doi: 10.3389/fmed.2023.1044402. eCollection 2023.
基于基因表达预测肿瘤微环境中的RNA假尿苷修饰及胶质瘤患者的预后
Front Cell Dev Biol. 2022 Jan 18;9:727595. doi: 10.3389/fcell.2021.727595. eCollection 2021.
4
The epitranscriptome beyond mA.非 mA 修饰的转录组学。
Nat Rev Genet. 2021 Feb;22(2):119-131. doi: 10.1038/s41576-020-00295-8. Epub 2020 Nov 13.
5
Prognosis Analysis and Validation of mA Signature and Tumor Immune Microenvironment in Glioma.胶质瘤中mA特征与肿瘤免疫微环境的预后分析及验证
Front Oncol. 2020 Oct 5;10:541401. doi: 10.3389/fonc.2020.541401. eCollection 2020.
6
Identification of RNA: 5-Methylcytosine Methyltransferases-Related Signature for Predicting Prognosis in Glioma.用于预测胶质瘤预后的RNA：5-甲基胞嘧啶甲基转移酶相关特征的鉴定
Front Oncol. 2020 Aug 19;10:1119. doi: 10.3389/fonc.2020.01119. eCollection 2020.
7
N6-Methylandenosine-Related lncRNAs Are Potential Biomarkers for Predicting the Overall Survival of Lower-Grade Glioma Patients.N6-甲基腺苷相关长链非编码RNA是预测低级别胶质瘤患者总生存期的潜在生物标志物。
Front Cell Dev Biol. 2020 Jul 23;8:642. doi: 10.3389/fcell.2020.00642. eCollection 2020.
8
TIMER2.0 for analysis of tumor-infiltrating immune cells.TIMER2.0 用于分析肿瘤浸润免疫细胞。
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514. doi: 10.1093/nar/gkaa407.
9
Results From the CheckMate 143 Clinical Trial: Stalemate or New Game Strategy for Glioblastoma Immunotherapy?CheckMate 143临床试验结果：胶质母细胞瘤免疫疗法陷入僵局还是采用新的游戏策略？
JAMA Oncol. 2020 Jul 1;6(7):987-989. doi: 10.1001/jamaoncol.2020.0857.
10
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.纳武利尤单抗对比贝伐珠单抗治疗复发性胶质母细胞瘤患者的效果：CheckMate 143 期随机临床试验。
JAMA Oncol. 2020 Jul 1;6(7):1003-1010. doi: 10.1001/jamaoncol.2020.1024.